???We are pleased that the NIMH has again awarded a grant to support our orphan GPCR research, comments Gregory A. Demopulos, M.D., chairman, and CEO. ???Omeros??? DTLacO platform can generate antibodies that target a wide range of diseases, including multiple types of cancer.